Heart Health

Heart Health Research

Cardiovascular diseases, such as heart attack, stroke, and congestive heart failure, are responsible for a major proportion of the health burden experienced by individuals and societies around the world. Not only is cardiovascular disease important because of the large numbers of people who die prematurely as a consequence, but it is also one of the leading causes of inequalities in health within and between populations.


The Heart Health research programme has undertaken over 20 years of research into the causes, prevention and treatment of cardiovascular disease. This theme’s primary focus is on the leading determinants of cardiovascular disease, in particular blood pressure and cholesterol, and identifying and developing practicable, affordable interventions to prevent cardiovascular disease.


Our research is international in scope, particularly in the Asia-Pacific region, as well as in New Zealand. It draws on the collective expertise of a leading group of clinical and population health researchers, and has considerable potential to improve health at a population level.


Our current research highlights


ANZACS-QI is a unique clinical registry and quality improvement tool for the management of people with Acute Coronary Syndrome (ACS) and other cardiac problems, admitted to hospitals across New Zealand.

It is a clinician-led initiative managed by NIHI and delivered in partnership with District Health Boards, the Ministry of Health and Enigma Solutions Limited.

ANZACS-QI supports the evidence-based management of ACS patients by securely gathering quality-audited clinical data on every suspected ACS patient in New Zealand.

By May 2016 over 25,000 people with ACS and over 50,000 people referred for coronary angiography had been registered in the ANZACS-QI database.

The trial is funded by the Ministry of Health
For more information please contact Professor Chris Bullen



A community-based, double-blind, randomised controlled trial to evaluate the effect of 150mg aspirin or placebo daily for up to 24 weeks on venous ulcer healing. Participants will also receive compression therapy as delivered through district nursing services at the study centres.

Aspirin4VLU is an investigator-initiated trial designed and co-ordinated in collaboration with:

  • Auckland District Health Board
  • Counties Manukau District Health Board
  • Southern District Health Board
  • The Nurse Maude Association Christchurch
  • Waikato District Health Board

The trial is funded by the Health Research Council of New Zealand.
For more information please contact Associate Professor Andrew Jull